Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label, Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with 22q11.2 Deletion Syndrome

Next Previous
Trial Profile

Open-Label, Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with 22q11.2 Deletion Syndrome

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications DiGeorge syndrome
  • Focus Adverse reactions
  • Acronyms INSPIRE
  • Sponsors Zynerba Pharmaceuticals

Most Recent Events

  • 05 Dec 2023 According to a Harmony Biosciences media release, data from this trial will be presented at the American College of Neuropsychopharmacology Annual Meeting 2023.
  • 14 Sep 2023 Results presented in the Zynerba Pharmaceuticals Media Release.
  • 15 May 2023 According to a Zynerba Pharmaceuticals media release, company presented data at the 55th Gatlinburg Conference in April 2023 that showed through 38-weeks of treatment, statistically significant improvements were seen in children and adolescents treated with Zygel.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top